The course of melanoma-associated vitiligo: report of a case

被引:22
作者
Daneshpazhooh, Maryam
Shokoohi, Ali
Dadban, Ali
Raafat, Jahangir
机构
[1] Univ Tehran Med Sci, Dept Dermatol, Tehran, Iran
[2] Univ Tehran Med Sci, Dept Oncol, Tehran, Iran
[3] Avignon Gen Hosp, Dept Dermatol, Avignon, France
关键词
chemo-immunotherapy; interferon-alpha; melanoma; vitiligo;
D O I
10.1097/01.cmr.0000222590.68234.1d
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The appearance of vitiligo-like lesions in patients with malignant melanoma is a well-known yet uncommon phenomenon. This finding is especially reported in patients undergoing immunotherapy with or without chemotherapy for malignant melanoma and is generally believed to be associated with a better prognosis. We report a case of preexisting vitiligo in a 48-year-old man, aggravated after chemo-immunotherapy of pulmonary metastatic melanoma with interferon-alpha, vinblastine and dacarbazine. Skin lesions remained stable after discontinuation of the treatment, and repigmentation heralded the recurrence of metastatic disease. These findings were in favor of vitiligo being a marker of the immunity against melanoma cells and its favorable impact on the prognosis of melanoma patients.
引用
收藏
页码:371 / 373
页数:3
相关论文
共 35 条
[1]   Melanoma and vitiligo: Immunology's Grecian urn [J].
Berd, D ;
Mastrangelo, MJ ;
Lattime, E ;
Sato, T ;
Maguire, HC .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 42 (05) :263-267
[2]  
Bronte V, 2000, CANCER RES, V60, P253
[3]  
BuendiaEisman A, 1997, EUR J DERMATOL, V7, P522
[4]   PROGNOSTIC-SIGNIFICANCE OF HYPOPIGMENTATION IN MALIGNANT-MELANOMA [J].
BYSTRYN, JC ;
RIGEL, D ;
FRIEDMAN, RJ ;
KOPF, A .
ARCHIVES OF DERMATOLOGY, 1987, 123 (08) :1053-1055
[5]   Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2 [J].
Chianese-Bullock, KA ;
Woodson, EMH ;
Tao, HM ;
Boerner, SA ;
Smolkin, M ;
Grosh, WW ;
Neese, PY ;
Merrill, P ;
Petroni, GR ;
Slingluff, CL .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (04) :412-419
[6]   MELANOMA AND VITILIGO ARE ASSOCIATED WITH ANTIBODY-RESPONSES TO SIMILAR ANTIGENS ON PIGMENT-CELLS [J].
CUI, J ;
BYSTRYN, JC .
ARCHIVES OF DERMATOLOGY, 1995, 131 (03) :314-318
[7]   Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination:: A phase I trial in metastatic melanoma [J].
Di Nicola, M ;
Carlo-Stella, C ;
Mortarini, R ;
Baldassari, P ;
Guidetti, A ;
Gallino, GF ;
Del Vecchio, M ;
Ravagnani, F ;
Magni, M ;
Chaplin, P ;
Cascinelli, N ;
Parmiani, G ;
Gianni, AM ;
Anichini, A .
CLINICAL CANCER RESEARCH, 2004, 10 (16) :5381-5390
[8]  
Fishman P, 1997, CANCER, V79, P1461, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1461::AID-CNCR3>3.0.CO
[9]  
2-E
[10]   Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? [J].
Garbelli, S ;
Mantovani, S ;
Palermo, B ;
Giachino, C .
PIGMENT CELL RESEARCH, 2005, 18 (04) :234-242